首页> 外文期刊>Brain research >Exogenous kallikrein enhances neurogenesis and angiogenesis in the subventricular zone and the peri-infarction region and improves neurological function after focal cortical infarction in hypertensive rats.
【24h】

Exogenous kallikrein enhances neurogenesis and angiogenesis in the subventricular zone and the peri-infarction region and improves neurological function after focal cortical infarction in hypertensive rats.

机译:外源激肽释放酶增强高血压大鼠局灶性皮层梗死后脑室下区域和梗塞周围区域的神经发生和血管生成,并改善神经功能。

获取原文
获取原文并翻译 | 示例
           

摘要

Kallikrein, a serine proteinase, has been identified as an angiogenic growth factor recently. We investigated whether delayed treatment with exogenous kallikrein enhances neurogenesis and angiogenesis after focal cortical infarction in stroke-prone renovascular hypertensive rats. Human tissue kallikrein (1.6x10(-2) PNAU/kg) or vehicle was given through a tail vein daily for 6 consecutive days starting 24 h after distal middle cerebral artery occlusion (MCAO). Cell proliferation was examined by using 5'-bromo-2'-deoxyuridine (BrdU, 50 mg/kg). Rats were sacrificed at 3, 7, 14 or 28 d after MCAO, respectively. Treatment with kallikrein significantly increased the number of BrdU(+) cells in the subventricular zone (SVZ) and the peri-infarction region initiating 3 d after MCAO compared with the vehicle group (all p<0.05). Kallikrein significantly increased the number of BrdU(+)/DCX(+) cells and BrdU(+)estin(+) cells in the SVZ as well as vascular density in the peri-infarction region compared with the vehicle group (all p<0.05), which increased at 3 d, peaked at 7-14 d after MCAO, and then gradually decreased. Kallikrein markedly increased the number of BrdU(+)/NeuN(+) cells in the peri-infarction region compared with the vehicle group at 14 d and 28 d after MCAO (all p<0.05). The kallikrein group showed better functional improvement after stroke (all p<0.05). Our study demonstrates that delayed administration of kallikrein at 24 h after cortical infarction promotes the SVZ neuroblasts proliferation, migration, and selective differentiation. Moreover, kallikrein enhanced endogenous neurogenesis is associated with angiogenesis, both attributing to functional improvement after stroke. Therefore, kallikrein may have a potential therapeutic perspective on ischemic stroke.
机译:激肽释放酶是一种丝氨酸蛋白酶,最近已被确定为血管生成生长因子。我们调查了中风倾向性肾血管性高血压大鼠局灶性脑梗死后,外源激肽释放酶的延迟治疗是否能增强神经发生和血管生成。大脑中部远端动脉闭塞(MCAO)后24小时开始,连续6天每天通过尾静脉给予人类组织激肽释放酶(1.6x10(-2)PNAU / kg)或媒介。通过使用5'-溴-2'-脱氧尿苷(BrdU,50mg / kg)检查细胞增殖。分别在MCAO后3、7、14或28天处死大鼠。与溶媒组相比,MCAO后3 d开始,激肽释放酶治疗显着增加了脑室下区域(SVZ)和梗死周围区域中BrdU(+)细胞的数量(所有p <0.05)。与媒介物组相比,激肽释放酶显着增加了SVZ中BrdU(+)/ DCX(+)细胞和BrdU(+)/ nestin(+)细胞的数量以及梗死周围区域的血管密度(所有p < 0.05),在3天时增加,在MCAO后的7-14天达到峰值,然后逐渐下降。与媒介物组相比,在MCAO后14 d和28 d,激肽释放酶显着增加了梗死周围区域BrdU(+)/ NeuN(+)细胞的数量(所有p <0.05)。激肽释放酶组在卒中后表现出更好的功能改善(所有p <0.05)。我们的研究表明,皮层梗死后24 h激肽释放酶的延迟给药可促进SVZ神经母细胞的增殖,迁移和选择性分化。此外,激肽释放酶增强的内源性神经发生与血管生成有关,均与中风后的功能改善有关。因此,激肽释放酶可能对缺血性中风具有潜在的治疗前景。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号